Variation in human gut microbiota impacts tamoxifen pharmacokinetics
ABSTRACT Tamoxifen is the most prescribed drug used to prevent breast cancer recurrence, but patients show variable responses to tamoxifen. Such differential inter-individual response has a significant socioeconomic impact as one in eight women will develop breast cancer and nearly half a million pe...
Saved in:
Main Authors: | Yasmine Alam, Sheron Hakopian, Lizett Ortiz de Ora, Ian Tamburini, Julio Avelar-Barragan, Sunhee Jung, Zane Long, Alina Chao, Katrine Whiteson, Cholsoon Jang, Elizabeth Bess |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2025-01-01
|
Series: | mBio |
Subjects: | |
Online Access: | https://journals.asm.org/doi/10.1128/mbio.01679-24 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bilosomal Co-Encapsulated Tamoxifen and Propranolol for Potentiated Anti-Breast Cancer Efficacy: In Vitro and In Vivo Investigation
by: Toka T. Elebyary, et al.
Published: (2025-01-01) -
LINC00626 drives tamoxifen resistance in breast cancer cells by interaction with UPF1
by: Hui Yuan, et al.
Published: (2025-01-01) -
Machine learning Nomogram for Predicting endometrial lesions after tamoxifen therapy in breast Cancer patients
by: Cao Shaoshan, et al.
Published: (2025-01-01) -
Rapamycin inhibits tamoxifen-induced endometrial proliferation in vitro as a pilot approach for endometrial protection in breast cancer
by: Akiko Nakamura, et al.
Published: (2025-01-01) -
Cardamom extract alleviates tamoxifen-induced liver damage by suppressing inflammation and pyroptosis pathway
by: Wedad S. Sarawi, et al.
Published: (2025-02-01)